Company: PolyPid Ltd.
Ticker: Nasdaq: PYPD
Sector: Healthcare
Investor Contact: Ben Shamsian

PolyPid News

News

PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility

Secured Loan facility with Kreos Capital Extends Company's Cash Runway into the Second Quarter of 2023PETACH TIKVA, Israel, April 06, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes,...

PolyPid to Deliver Poster Presentation at SAGES 2022

Presentation Evaluates Efficacy of D-PLEX100 in Reducing Surgical Site Infection Rates in Elective Colorectal Surgery PETACH TIKVA, Israel, March 08, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve...

PolyPid to Present at the Barclays Global Healthcare Conference

PETACH TIKVA, Israel, March 01, 2022 -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today...

Skip to content